Impact of Muscarinic M 3 Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients : A Case-Controlled Study

Background M3 muscarinic receptor antagonism has been associated with glucose intolerance and disturbance of insulin secretion. Objective Our objective was to examine the risk of type 2 diabetes mellitus (T2DM) in patients using antidepressants with and without M3 muscarinic receptor antagonism (AD_antaM3 and AD_nonantaM3, respectively). Methods We designed a case–control study using a pharmacy prescription database. We selected a cohort of patients who initiated antidepressant use between the ages of 20 and 40 years and who did not receive any anti-diabetic prescriptions at baseline. Cases were defined as those who developed T2DM [i.e., receiving oral anti-diabetic medication, Anatomical Therapeutic Chemical (ATC) code A10B] during the follow-up period (1994–2014), and ten random controls were picked for each case from the cohort of patients who did not develop T2DM. Results A total of 530 cases with incident T2DM and 5300 controls were included. Compared with no use of antidepressants during the previous 2 years, recent (within the last 6 months) exposure to AD_antaM3 was associated with a moderately increased risk of T2DM: adjusted odds ratio 1.55 (95% confidence interval 1.18–2.02). In the stratified analyses, this association was dose dependent ([365 defined daily doses) and significant for patients who were in the younger age group (\45 years at the end of followup), were female and had no co-morbidity. On the other hand, recent exposure to AD_nonantaM3 was not associated with a risk for T2DM in any of our analyses. Conclusion Our results suggest that exposure to AD_antaM3 was associated with the development of T2DM among antidepressant users.

[1]  U. Krus,et al.  Altered serotonin (5-HT) 1D and 2A receptor expression may contribute to defective insulin and glucagon secretion in human type 2 diabetes , 2015, Peptides.

[2]  M. Irizarry,et al.  Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine. , 2015, Current drug safety.

[3]  Sang Won Seo,et al.  Effect of Psychotropic Drugs on Development of Diabetes Mellitus in Patients With Alzheimer's Disease , 2015, Medicine.

[4]  I. Umar,et al.  Age-dependent alteration of antioxidant defense system in hypertensive and type-2 diabetes patients , 2015, Journal of Diabetes & Metabolic Disorders.

[5]  Xia Yang,et al.  Shared Molecular Pathways and Gene Networks for Cardiovascular Disease and Type 2 Diabetes Mellitus in Women Across Diverse Ethnicities , 2014, Circulation. Cardiovascular genetics.

[6]  U. Sambamoorthi,et al.  Use of antidepressants and statins and short-term risk of new-onset diabetes among high risk adults. , 2014, Diabetes research and clinical practice.

[7]  Varsha G. Vimalananda,et al.  Depressive Symptoms, Antidepressant Use, and the Incidence of Diabetes in the Black Women’s Health Study , 2014, Diabetes Care.

[8]  Xiao-dong Liu,et al.  Co-administration of paroxetine and pravastatin causes deregulation of glucose homeostasis in diabetic rats via enhanced paroxetine exposure , 2014, Acta Pharmacologica Sinica.

[9]  M. Lai,et al.  Long-term antidepressant use and the risk of type 2 diabetes mellitus: a population-based, nested case-control study in Taiwan. , 2014, The Journal of clinical psychiatry.

[10]  N. Maclaren,et al.  Etiology and Pathogenesis of Diabetes Mellitus IN Children , 2013 .

[11]  Li An,et al.  Co‐medication of pravastatin and paroxetine—A categorical study , 2013, Journal of clinical pharmacology.

[12]  Xu-Feng Huang,et al.  Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor , 2013, CNS Drugs.

[13]  U. Sambamoorthi,et al.  Antidepressant use, depression, and new‐onset diabetes among elderly Medicare beneficiaries (在老年医疗保险受益者中调查抗抑郁药的使用、抑郁症以及新发糖尿病) , 2013, Journal of diabetes.

[14]  Maarten J Postma,et al.  The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges , 2013, Expert review of pharmacoeconomics & outcomes research.

[15]  G. Remington,et al.  Atypical antipsychotics and effects of adrenergic and serotonergic receptor binding on insulin secretion in-vivo: An animal model , 2013, Schizophrenia Research.

[16]  Kunihiro Suzuki,et al.  Cell-Based Screening Identifies Paroxetine as an Inhibitor of Diabetic Endothelial Dysfunction , 2013, Diabetes.

[17]  E. Mannucci,et al.  Depression as a risk factor for diabetes: a meta-analysis of longitudinal studies. , 2013, The Journal of clinical psychiatry.

[18]  J. P. Wilson,et al.  Use of antidepressant agents and the risk of type 2 diabetes , 2011, European Journal of Clinical Pharmacology.

[19]  S. M. Setter,et al.  Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia , 2011, Diabetes Spectrum.

[20]  P. de Jonge,et al.  Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. , 2010, The American journal of psychiatry.

[21]  H. Kendig,et al.  Diabetes incidence associated with depression and antidepressants in the Melbourne Longitudinal Studies on Healthy Ageing (MELSHA) , 2009, International journal of geriatric psychiatry.

[22]  S. Suissa,et al.  Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. , 2009, The American journal of psychiatry.

[23]  A. Egberts,et al.  No increased incidence of diabetes in antidepressant users , 2007, International clinical psychopharmacology.

[24]  M. Tancer,et al.  Metabolic syndrome: relevance to antidepressant treatment. , 2006, Journal of psychiatry & neuroscience : JPN.

[25]  M. Keshavan,et al.  Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology. , 2006, Journal of clinical psychopharmacology.

[26]  S. Kennedy,et al.  The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms , 2006, Expert opinion on drug safety.

[27]  H. Tobi,et al.  Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. , 2004, Journal of clinical epidemiology.

[28]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[29]  E. Richelson,et al.  Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics. , 1993, Biochemical pharmacology.

[30]  E H Wagner,et al.  A chronic disease score from automated pharmacy data. , 1992, Journal of clinical epidemiology.

[31]  J. Manson,et al.  Use of antidepressant medication and risk of type 2 diabetes: results from three cohorts of US adults , 2011, Diabetologia.

[32]  R. Holman,et al.  Initial management of blood glucose in type 2 diabetes mellitus , 2010 .

[33]  R. Hardy,et al.  Depressive symptoms and risk of type 2 diabetes in a national sample of middle-aged and older adults. The English Longitudinal Study of Aging. Running Title: Depressive symptoms and incident diabetes , 2010 .

[34]  K. Takeuchi,et al.  Possible involvement of endogenous 5-HT in aggravation of cerulein-induced acute pancreatitis in mice. , 2007, Journal of pharmacological sciences.